Skip to main content
Premium Trial:

Request an Annual Quote

WIN Consortium to Use Foundation Medicine Test in 200-Patient Trial Starting 2013


The Worldwide Innovative Networking Consortium in personalized cancer medicine plans to use Foundation Medicine's cancer genome profiling test in an upcoming clinical trial, the company said last week.

A company spokesperson told Clinical Sequencing News that the trial will involve 200 patients, who will be enrolled starting in early 2013. Each patient will be evaluated with the firm's sequencing-based test, FoundationOne, and be matched to a targeted therapy where possible.

The test "will allow physicians participating in this trial to test for alterations in clinically relevant genes known to be associated with human cancer and match these alterations with appropriate targeted therapies or clinical trials," said John Mendelsohn, chairman of the WIN Consortium, in a statement.

The WIN Consortium, which Foundation Medicine joined in March, is an international network of 22 academic institutions and companies. It was started by the Cancer Institute Gustave Roussy in France and the University of Texas MD Anderson Cancer Center and focuses on international biomarker-driven therapeutic clinical trials.

Foundation Medicine launched its test in May and said recently that it plans to conduct several clinical trials to show the test's efficacy and its impact on doctors' decisions (CSN 6/13/2012).

The test sequences 3,230 exons of 182 genes known to be mutated in solid tumors, as well as 37 introns from 14 genes known to be rearranged in these cancers.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.